Exclusive Summary

• Unique Mechanism (First-in-Concept): A rare GLP-1/GLP-2 dual agonist focusing on 'Healthy Weight Loss.' The GLP-2 component promotes lean mass preservation while reducing fat, addressing the critical issue of muscle loss associated with current GLP-1 therapies.
• Superior Safety Profile: Preclinical toxicity studies (26 weeks) show no evidence of hyperplasia in the stomach, intestine, or thyroid, offering a cleaner safety profile compared to Semaglutide and Teduglutide for long-term use.
• Outstanding Cost Efficiency: High-yield manufacturing (>7 g/L) results in extremely low Cost of Goods Sold (COGS), providing significant flexibility for global pricing strategies and reimbursement negotiations.
• Delivery Innovation: Beyond the injectable form, the asset includes a validated oral capsule version (UB351) with remarkably high bioavailability (80-160%), enabling a potential 'Once-Weekly Oral' blockbuster product.

Asset Materials

Contact Us for Full Materials